Skip to main content
OpenTrials
Completed

NCT Number: NCT06783686

Evaluation of NV701 (Pilocarpine 1.25%) Compared With Vuity (Pilocarpine 1.25%) on Pupil Size in Subjects With Presbyopia

Randomized contralateral eye study to evaluate the effect of one-time dosing of NV701 versus commercially available 1.25% pilocarpine solution on pupil size.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Arizona Eye Center, Chandler, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 40-55 years with presbyopia
  • Able to understand and willing to sign the informed consent for the study
  • Resting mesopic pupil diameter of >4 mm in both eyes
  • Change in mesopic pupil diameter of >1 mm after 1 hour in response to pilocarpine 1.25% in both eyes
  • Willing to abstain from contact lens use for 7 days before the study visit
  • Women of childbearing age must have a negative urine pregnancy test at the screening visit and be willing to use a reliable method of birth control during the study

Exclusion criteria

  • Anisocoria >1 mm in photopic or mesopic conditions
  • High myopia (-6.00 diopters or greater)
  • Any iris abnormality making it difficult to judge pupil diameter as determined by the principal investigator
  • Known allergy to any of the study products or medications
  • Concurrent use of any topical prescription ophthalmic products
  • History of uveitis or intraocular inflammation
  • Inability to complete any of the study procedures
  • History of ocular surgery other than LASIK or PRK
  • History of retinal tear or retinal detachment
  • Presence of retinal lattice degeneration, operculated hole, or other retinal pathology on screening exam.
  • History of punctal plugs or punctal cautery in one or both eyes
  • History of nasolacrimal duct surgery in one or both eyes
  • History of blepharoplasty or ptosis surgery in one or both eyes
  • History of glaucoma, glaucoma suspect or ocular hypertension diagnosis
  • History of acute angle closure or laser peripheral iridotomy
  • History of moderate or severe dry eye disease
  • Females who are pregnant, nursing, or planning a pregnancy during the study
  • Females of childbearing potential and males with partners of childbearing potential who do not agree to use reliable contraception during the study
  • Uncontrolled systemic disease

Treatment and study plan

NV701

Drug

eye drop

Pilocarpine 1.25% Eye drop

Drug

eye drop

Primary outcomes

  1. Change in pupil size over 8 hours

    Time frame: 8 hours

    Area under the curve (AUC) of the change in mesopic pupil diameter over 8 hours after eye drop dosing

Secondary outcomes

  1. Mesopic pupil diameter difference

    Time frame: 8 hours

    Absolute difference in mesopic pupil diameter at 1, 2, 3, 4, 5, 6, 7, and 8 hours after administration

Sponsors and collaborators

Lead sponsor

Novus Vision LLC

Industry

Registry information

Official study title

Effect on Pupil Size After One-time Administration of NV701 (Pilocarpine 1.25%) vs. Vuity (Pilocarpine 1.25%)

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 20, 2025
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.